Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 3144 | (+)-Blebbistatin | Negative control of (±)-Blebbistatin as an inhibitor of class II myosins | €90.00 | |
| 2467 | (+)-ITD-1 | Selective inhibitor of TGFβ/Smad signaling that promotes cardiogenesis | €165.00 | |
| 1989 | (+)-JQ1 |
Potent and selective BET bromodomain inhibitor |
€60.00 | |
| 3822 | (+)-JQ1 carboxylic acid | (+)-JQ1 derivative; PROTAC precursor | €110.00 | |
| 1730 | (+)-Kifunensine | α-mannosidase inhibitor | €120.00 | |
| 2239 | (+)-ZK 216348 | Selective nonsteroidal glucocorticoid receptor (GR) agonist | €125.00 | |
| 3074 | (-)-Blebbistatin | Selective inhibitor of class II myosins; Active enantiomer of (±)-Blebbistatin | €90.00 | |
| 3873 | (-)-JQ-1 | Inactive enantiomer of (+)-JQ1 | €120.00 | |
| 3759 | (aR)-RP-6306 | (aR)-enantiomer of RP-6306 (Axon 3668); PKMYT1 inhibitor | €180.00 | |
| 1758 | (R)-(+)-BAY K 8644 | Calcium (Ca2+) channel modulator | €120.00 | |
| 1229 | (R)-(-)-Rolipram | PDE4 inhibitor | €110.00 | |
| 2830 | (R)-CE3F4 | Potent inhibitor of EPAC1 | €120.00 | |
| 3743 | (R)-HTS-3 hydrochloride | First potent, selective, and cell-active LPCAT3 inhibitor | €150.00 | |
| 3928 | (R)-SKBG-1 | Covalent RNA-binding protein NONO ligand | €160.00 | |
| 1432 | (S)-(+)-Rolipram | PDE4 inhibitor | €115.00 | |
| 1759 | (S)-(-)-BAY K 8644 | Calcium (Ca2+) channel activator (L-type voltage-gated) | €120.00 | |
| 4192 | (S)-BI 2536 | Dual PLK1/BRD4 bromodomain inhibitor | €170.00 | |
| 2296 | (S)-Crizotinib | MTH1 inhibitor | €85.00 | |
| 3704 | (S)-ErSO | Inactive enantiomer of ErSO | €180.00 | |
| 3929 | (S)-SKBG-1 | Inactive enantiomer of (R)-SKBG-1 | €150.00 | |
| 4093 | (Z)-4-Hydroxytamoxifen | The more active metabolite of Tamoxifen (SERM; Axon 3252) | €110.00 | |
| 2221 | (Z)-Endoxifen | The more active (Z)-isomer of Endoxifen (SERM; Axon 2190) | €150.00 | |
| 2718 | (±)-Blebbistatin | Potent and specific inhibitor of class II myosins | €95.00 | |
| 1687 | (±)-E-Homocamptothecin | Potent topoisomerase I (Topo 1) inhibitor | €120.00 | |
| 2537 | 1,5-Isoquinolinediol | PARP1 inhibitor and neuroprotective agent | €50.00 | |
| 2434 | 1-Deazaadenosine | Adenosine deaminase (ADA) inhibitor with cytostatic activity in vitro | €140.00 | |
| 1892 | 1-NM-PP1 | Potent tyrosine kinase inhibitor (TKI) of multiple targets (Src, Fyn, Abl, CDK, Trk) | €95.00 | |
| 2222 | 10058-F4 | c-Myc inhibitor inducing cell-cycle arrest at G0/G1 phase | €80.00 | |
| 3617 | 1R,3R-RSL3 (negative control) | Negative control of 1S,3R-RSL3 as GPX4 inhibitor | €90.00 | |
| 2496 | 2,5-Dimethylcelecoxib | Celecoxib analog with anti-tumor properties, lacking COX-2 inhibitory activity | €75.00 | |